Virus like vesicles technology that can be exploited to generate safe and potent vaccines
CaroGen Corporation has developed transformative virus-like vesicles (VLVs) technology that can be exploited to generate safe but potent vaccines to treat various diseases. The technology was developed by Yale Professor John Rose and has been validated in proof-of-concept studies. CaroGen is currently raising between $7 to $10 million to prepare for and complete a Phase I human clinical trial of its hepatitis B vaccine (HBV) using this technology as well as proof-of-concept in animal models for additional disease targets.
Bijan Almassian, Co-Founder/CEO
Valerian Nakaar, Co-Founder/VP